Document is current
Any future updates will be listed below
-
Authors
Padrão, Nuno
Severson, Tesa M.
Gregoricchio, Sebastian https://orcid.org/0000-0001-9209-5403
Guijarro, Ana https://orcid.org/0000-0002-1595-2173
Lutz, Catrin
Taranto, Daniel
Hutten, Stefan
Ligorio, Francesca
Persia, Angelica
Roest, Merel
Sanders, Joyce
Song, Ji-Ying
Pires-Oliveira, Sara https://orcid.org/0000-0002-6586-9079
Donaldson Collier, Maria
Horlings, Hugo https://orcid.org/0000-0003-4782-8828
Pisciotta, Livia https://orcid.org/0000-0001-7080-9807
de Braud, Filippo
Vernieri, Claudio
Akkari, Leila https://orcid.org/0000-0001-5479-641X
Jonkers, Jos https://orcid.org/0000-0002-9264-9792
Nencioni, Alessio https://orcid.org/0000-0001-5068-8884
Caffa, Irene https://orcid.org/0000-0003-1111-9915
Zwart, Wilbert https://orcid.org/0000-0002-9823-7289
- License Information
-
More Information
Article History
Received: 29 February 2024
Accepted: 5 November 2025
First Online: 10 December 2025
Competing interests
: A.N. and I.C. hold intellectual property rights on clinical uses of FMDs. C.V. and F.d.B. hold intellectual property rights on clinical uses of FMDs. F.L. reports honoraria as a speaker from Novartis, Pfizer and Accademia Nazionale di Medicina. C.V. and F.d.B. report roles in advisory boards, consultancy activity or having received honoraria as speakers from Pfizer, Novartis, Eli Lilly, Astra Zeneca, Daiichi Sankyo, Menarini Stemline, Gilead, MSD and Istituto Gentili. The other authors declare no competing interests.
